Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) Patents (Class 424/94.6)
- Serine proteinases (3.4.21) (e.g., trypsin, chymotrypsin, plasmin, thrombin, elastase, kallikrein, fibrinolysin, streptokinease, etc.) (Class 424/94.64)
- SH-proteinases (3.4.22) (e.g., papain, chymopapain, bromelains, ficin, etc.) (Class 424/94.65)
- Acid proteinases (3.4.23) (e.g., pepsin, renin, chymosin, etc.) (Class 424/94.66)
- Metalloproteinases (3.4.24) (e.g., collagenase, snake venom zinc proteinase, etc.) (Class 424/94.67)
-
Patent number: 10106854Abstract: The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer.Type: GrantFiled: June 14, 2013Date of Patent: October 23, 2018Assignees: Aarhus Universitet, Region MidtjyllandInventors: Torben Falck Ørntoft, Karina Dalsgaard Sørensen, Christa Haldrup
-
Patent number: 10093909Abstract: Polypeptides having phytase activity and polynucleotide sequences encoding the phytases are provided. The gene expresses the phytase at a level of at least 7 g/l to 40 g/L. The phytases have higher specific activity, retain activity at low pH, retain activity at high temperature, increased phosphorous equivalency, increased phosphorous bioavailability, and increased phosphorous hydrolysis. The phytases can be used in a variety of industries including food, feed, ethanol production, pharmaceuticals, and cleaning.Type: GrantFiled: March 10, 2014Date of Patent: October 9, 2018Assignee: BASF ENZYMES LLCInventor: Arne I. Solbak, Jr.
-
Patent number: 10081800Abstract: Novel lactonases are provided.Type: GrantFiled: August 3, 2017Date of Patent: September 25, 2018Assignee: Fornia BioSolutions, Inc.Inventors: Goutami Banerjee, Jie Yang, Khin Oo, Xiyun Zhang, Eric Lin Hu, Tatsuya Fukushima
-
Patent number: 10058596Abstract: Methods and compositions for the enzymatic debridement of wounds are provided. Methods for preparing enzymatic debridement compositions are also provided. In one embodiment, an enzymatic debridement composition prepared by dissolving crude bromelain in a composition comprising a weak acid, and filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition is provided.Type: GrantFiled: December 18, 2012Date of Patent: August 28, 2018Assignee: KCI Licensing, Inc.Inventor: Douglas Philip Hanson
-
Patent number: 10016559Abstract: Embodiments relate to systems, methods and devices for delivering a drug or other therapy to a patient with an ambulatory infusion pump configured to provide a series of tolerance-building steps leading up to a plateau delivery rate. The plateau delivery rate is maintained until the prescribed amount of drug or therapy fluid is delivered to the patient. Embodiments of the invention include providing the patient or other user with a mechanism to decrease, or step down, the therapy delivery rate if a tolerance was not achieved at a lower rate, and providing notifications prior to a step up in a dosage delivery rate.Type: GrantFiled: October 28, 2014Date of Patent: July 10, 2018Assignee: Smiths Medical ASD, Inc.Inventors: David DeBelser, Clinton Robert Hetchler, David Pardee Sours, Michael Wade Kersch
-
Patent number: 9976187Abstract: Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.Type: GrantFiled: June 11, 2013Date of Patent: May 22, 2018Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Vladimir Bajic, Hicham Mansour, Roberto Incitti
-
Patent number: 9949925Abstract: Disclosed herein are bactericidal compositions that are effective against pathogenic biofilms, especially against biofilms formed by Pseudomonas aeruginosa. The disclosed compositions comprise escapin intermediate products which can reduce the biofilm viability and biofilm matrix of P. aeruginosa.Type: GrantFiled: April 1, 2016Date of Patent: April 24, 2018Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Charles D. Derby, Phang C. Tai, Eric S. Gilbert
-
Patent number: 9931437Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.Type: GrantFiled: February 4, 2015Date of Patent: April 3, 2018Assignee: WORCESTER POLYTECHNIC INSTITUTEInventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
-
Patent number: 9914916Abstract: The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.Type: GrantFiled: January 27, 2016Date of Patent: March 13, 2018Assignee: THE ROCKEFELLER UNIVERSITYInventors: Vincent A. Fischetti, Gregory Resch
-
Patent number: 9896672Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: GrantFiled: June 16, 2016Date of Patent: February 20, 2018Assignees: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Patent number: 9889203Abstract: Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.Type: GrantFiled: March 14, 2014Date of Patent: February 13, 2018Assignee: AMICUS THERAPEUTICS, INC.Inventor: Hung Do
-
Patent number: 9867875Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.Type: GrantFiled: May 18, 2016Date of Patent: January 16, 2018Assignee: BIO-CANCER TREATMENT INTERNATIONAL LIMITEDInventors: Gernot Schabbauer, Stephen Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
-
Patent number: 9844585Abstract: An embodiment of the invention is directed to a microfabricated, silicon-based, Convection Enhanced Delivery (CED) device. The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned fluid exit ports disposed at one or more respective locations of the channel and a fluid (drug) input opening. The fluid input opening may be configured or adapted to be connected to a fluid reservoir and/or a pump and/or a meter and/or a valve or other suitable control device(s) or apparatus that supplies and/or delivers fluid (e.g., a drug) to the microfabricated device. The device may have multiple channels disposed side by side or in different surfaces of the device. The device may be rigid, or flexible, in which case a flexible device can be attached to a bio-degradable support scaffold that provides sufficient structural rigidity for insertion of the device into the target tissue.Type: GrantFiled: June 25, 2014Date of Patent: December 19, 2017Assignees: YALE UNIVERSITY, CORNELL UNIVERSITYInventors: William L. Olbricht, Keith B. Neeves, Conor Foley, Russell T. Matthews, W. Mark Saltzman, Andrew Sawyer
-
Patent number: 9839679Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.Type: GrantFiled: February 26, 2014Date of Patent: December 12, 2017Assignee: Acorda Therapeutics, Inc.Inventors: Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
-
Patent number: 9839676Abstract: The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist.Type: GrantFiled: May 10, 2013Date of Patent: December 12, 2017Assignees: Murray Goulburn Co-Operative Co., Limited, AGRICULTURE VICTORIA SERVICES PTY LTDInventors: Peter Hobman, Andrew Brown
-
Patent number: 9827264Abstract: A method and system for identifying and treating various medical conditions caused by toxins, pathogens, hormonal imbalances and other factors involving intravenous therapy.Type: GrantFiled: May 10, 2016Date of Patent: November 28, 2017Inventor: Wyatt J. Palumbo
-
Patent number: 9816006Abstract: A coating process includes the successive steps of preparing the zone to be treated. At least one coat of a primer is applied to the prepared zone to obtain a thickness ranging from 100 to 450 micrometers. The zone to be treated is then reconditioned and a least one top coat is applied to obtain a thickness ranging from 100 to 450 micrometers.Type: GrantFiled: December 19, 2013Date of Patent: November 14, 2017Assignee: SARL SIMONInventor: Dominique Simon
-
Patent number: 9814664Abstract: A composition for treating keratin surfaces to stimulate selective catabolysis and improve cellular viability comprising at least one autophagy activator and at least one DNA repair enzyme, and a method for improving selective catabolysis and cellular viability by treating with the composition.Type: GrantFiled: December 27, 2013Date of Patent: November 14, 2017Assignee: ELC Management LLCInventors: Nadine A. Pernodet, Donald F. Collins, Dawn Layman, Daniel B. Yarosh
-
Patent number: 9765313Abstract: The present invention relates to the field of genetic engineering, in particular, the present invention relates to a method for producing a phytase variant with an improved thermal stability, and a phytase variant and the use thereof. The phytase variant contains at least one proline modification, compared to the phytase from Escherichia coli and other mutants thereof. The phytase variants with the modification have preferably improved properties, such as the thermal stability, optimal reaction temperature, pH property, specific activity, protease resistance and performance in animal feeds.Type: GrantFiled: November 12, 2013Date of Patent: September 19, 2017Assignee: Feed Research Institute, Chinese Academy of Agricultural SciencesInventors: Bin Yao, Huoqing Huang, Huiying Luo, Chao Shao, Yingguo Bai, Yaru Wang, Peilong Yang, Pengjun Shi, Kun Meng, Heng Zhao, Rui Ma
-
Patent number: 9752197Abstract: The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.Type: GrantFiled: January 29, 2016Date of Patent: September 5, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Tae Jeong Oh
-
Patent number: 9719074Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.Type: GrantFiled: August 21, 2015Date of Patent: August 1, 2017Assignee: Shire Human Genetic Therapies, Inc.Inventors: Ferenc Boldog, Michael Heartlein
-
Patent number: 9714427Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.Type: GrantFiled: November 9, 2011Date of Patent: July 25, 2017Assignee: The University of North Carolina at Chapel HillInventors: Benjamin David Philpot, Mark John Zylka, Bryan Leo Roth, John Arthur Allen, Hsien-Sung Huang
-
Patent number: 9687534Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: GrantFiled: March 5, 2015Date of Patent: June 27, 2017Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Patent number: 9663775Abstract: The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: November 23, 2012Date of Patent: May 30, 2017Assignee: Novozymes A/SInventor: Kirk Matthew Schnorr
-
Patent number: 9655954Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.Type: GrantFiled: July 8, 2015Date of Patent: May 23, 2017Assignees: Icahn School of Medicine at Mount Sinai, Genzyme CorporationInventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
-
Patent number: 9651558Abstract: The invention relates to bacterial cell surface display of post-translationally modified heterologous proteins. Provided is an isolated nucleic acid construct encoding a proteinaceous substance comprising, from the N-terminus to the C-terminus, at least (a) an N-terminal a lantibiotic leader sequence; (b) an amino acid sequence of interest to be post-translationally modified to a dehydroresidue- or thioether-bridge containing polypeptide; (c) a hydrophilic cell-wall spanning domain; (d) a sortase recognition motif; (e) a hydrophobic membrane spanning domain and (f) a C-terminal charged membrane anchoring domain. Also provided is a Gram-positive host cell expressing the construct, as well as a library of host cells.Type: GrantFiled: July 6, 2011Date of Patent: May 16, 2017Assignee: LanthioPep B.V.Inventor: Tjibbe Bosma
-
Patent number: 9631186Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.Type: GrantFiled: October 28, 2015Date of Patent: April 25, 2017Assignee: Sangamo BioSciences, Inc.Inventor: Jianbin Wang
-
Patent number: 9597378Abstract: A blood coagulation factor VII derivative, a blood coagulation factor VIIa derivative, FacVII and FacVIIa conjugates are prepared by linking a polymer capable of extending the blood half-life to the derivative. FacVII and VIIa complexes each prepared by linking a carrier to the conjugate, genes encoding the FacVII and FacVIIa derivatives, expression vectors comprising the genes, transformants introduced with the expression vectors, a method for preparing the FacVII and FacVIIa derivatives using the transformants, a method for preparing the FacVIIa conjugate and complex, a FacVIIa complex prepared by the method, a pharmaceutical composition for the prevention or treatment of hemophilia comprising the derivative, conjugate, or complex as an active ingredient, and a pharmaceutical composition for blood coagulation comprising the derivative, conjugate, or complex as an active ingredient are described.Type: GrantFiled: October 5, 2012Date of Patent: March 21, 2017Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Jin Kim, Byung Sun Lee, Sung Hwan Hong, Yong Ho Huh, Sung Youb Jung, Se Chang Kwon
-
Patent number: 9597376Abstract: A lipoprotein lipase (LPL) protein for treating and/or preventing HTG and its associated diseases, including but not limited to acute pancreatitis (AP), and in particular, acute pancreatitis secondary to or exacerbated by hypertriglyceridemia, and hypertriglyceridemia and its associated diseases in general, including cardiovascular and metabolic diseases, endocrine disorders, and fat embolism syndrome.Type: GrantFiled: August 19, 2015Date of Patent: March 21, 2017Assignee: Shire Human Genetic Therapies, Inc.Inventors: Omar L. Francone, Lin Guey, Kevin Holmes, Bruce Tangarone, Matthew Traylor, Lenore von Krusenstiern, Tracy Dowie, Lieh Yoon Low, Bohong Zhang, Muthuraman Meiyappan, Angela Norton, Bettina Strack-Logue, Dianna Lundberg, Michael F. Concino
-
Patent number: 9592279Abstract: An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan.Type: GrantFiled: April 8, 2013Date of Patent: March 14, 2017Assignees: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, SEIKAGAKU CORPORATIONInventors: Yukihiro Matsuyama, Kenji Kadomatsu, Shiro Imagama, Akiomi Tanaka
-
Patent number: 9579365Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.Type: GrantFiled: April 14, 2015Date of Patent: February 28, 2017Assignee: Quintessence Biosciences, Inc.Inventors: Tony Klink, John Kink, Laura Strong
-
Patent number: 9546360Abstract: Compositions and methods for the treatment of thrombotic thrombocytopenic purpura are disclosed.Type: GrantFiled: June 23, 2014Date of Patent: January 17, 2017Assignee: The Children's Hospital of PhiladelphiaInventor: X. Long Zheng
-
Patent number: 9526786Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.Type: GrantFiled: January 28, 2014Date of Patent: December 27, 2016Assignees: The Trustee of Columbia University in the City of New York, The Regents of the University of MichiganInventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovic, John J. Tesmer, Remy L. Brim
-
Patent number: 9526765Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: GrantFiled: February 11, 2013Date of Patent: December 27, 2016Assignees: The Kitasato InstituteInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
-
Patent number: 9512413Abstract: The present invention relates to isolated polypeptides having organophosphorous hydrolase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: May 31, 2013Date of Patent: December 6, 2016Assignee: NOVOZYMES A/SInventors: Bjarne Gram Hansen, Steffen Danielsen, Lars Kobberoee Skov, Leonardo De Maria, Julie Bille Rannes
-
Patent number: 9492511Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.Type: GrantFiled: March 30, 2015Date of Patent: November 15, 2016Assignee: Shire Human Genetic Therapies, Inc.Inventor: Dave Nichols
-
Patent number: 9474792Abstract: Methods of treating or ameliorating metabolic diseases using a PLA2G12A polypeptide or PLA2G12A mutant polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes mellitus, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.Type: GrantFiled: March 13, 2014Date of Patent: October 25, 2016Assignee: Amgen Inc.Inventors: Daniel C. H. Lin, Jinghong Wang, Yang Li
-
Patent number: 9441002Abstract: The thiol modified oligonucleotides have vast number of applications in the field of nucleic acid chemistry. The conjugates generated by mono thiol groups are unstable at higher temperature, in high salt concentration buffers and in presence other thiols. There is strong need to develop a novel thiol modifier probes that can generate multiple thiol groups. Described herein are efficient processes and compounds, dithiolane phosphoramidites derivative and dithiolane succinyl supports. The advantage of our cyclic disulfide thiol modifier is multifold a) each incorporation introduces two thiol groups; b) it can be introduced at any desired site of oligonucleotides; c) The symmetrical branching nature of the spacer in the linker arm of dithiolane allows for clean oligo synthesis, where cleavage of the linker arm and thereby of loss of oligo chain is prevented.Type: GrantFiled: October 28, 2013Date of Patent: September 13, 2016Assignee: ChemGenes CorporationInventors: Suresh C. Srivastava, Santhosh Kumar Thatikonda, Sant K. Srivastav, Praveen K. Shukla, Alok Srivastava
-
Patent number: 9415014Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.Type: GrantFiled: July 28, 2011Date of Patent: August 16, 2016Assignee: Curemark, LLCInventors: Joan M. Fallon, Matthew Heil
-
Patent number: 9382525Abstract: The present invention provides a site-specific pegylated arginase conjugate and method for producing thereof. The site-specific pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method for producing the arginase conjugate comprises genetically modifying the gene encoding an arginase so that the PEG moiety can be attached to the enzyme at a predetermined, specific intended sites. This is achieved by removing the PEG-attaching amino acid residue(s) at undesirable site(s) while keeping or adding cysteine(s) at the desirable site(s) of the enzyme. Two exemplary embodiments of the pegylated arginase conjugate are directed to human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys45 of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys161 of the enzyme.Type: GrantFiled: July 19, 2013Date of Patent: July 5, 2016Assignee: The Hong Kong Polytechnic UniversityInventors: Yun Chung Leung, Wai-hung Lo
-
Patent number: 9315552Abstract: The subject of the present invention is a method of modifying proteinaceous toxins through the addition of an NLS motif. The resulting cytotoxin facilitates the selective elimination of proliferating cells, particularly tumor cells.Type: GrantFiled: December 29, 2011Date of Patent: April 19, 2016Assignee: BIOINFOBANK SP. Z O. O.Inventors: Anna Bujko, Magdalena Lukasiak, Jaroslaw Dastych, Miroslawa Skupinska, Ewelina Rodakowska, Leszek Rychlewski
-
Patent number: 9308227Abstract: The invention describes a microorganism of the order of lactic acid bacteria or an analog, fragment, derivative, mutant or combination thereof, wherein the microorganism, or analog, fragment, derivative, mutant or combination thereof can coaggregate with Streptococcus pyogenes.Type: GrantFiled: May 16, 2012Date of Patent: April 12, 2016Assignee: ORGANOBALANCE MEDICAL AGInventors: Christine Lang, Andreas Raab, Natalia Bolotina
-
Patent number: 9284544Abstract: The present invention relates to cleaning compositions comprising variants of an alpha-amylase and methods of treating surfaces such as textiles with aqueous liquor comprising such compositions, especially at low temperatures.Type: GrantFiled: June 29, 2012Date of Patent: March 15, 2016Assignee: The Procter & Gamble CompanyInventors: Michelle Jackson, Philip Frank Souter, Lindsay Suzanne Bewick, Svend Kaasgaard, Jens Oebro, Signe Eskildsen Larsen, Allan Svendsen, Annette Helle Johansen, Michael Skjoet, Carsten Andersen, Lars Beier, Esben Peter Friis, Miguel Duarte Guilherme Pereira Toscano, Mads Bjoernvad, Frank Winther Rasmussen, Liv Spaangner Christiansen
-
Patent number: 9255262Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases.Type: GrantFiled: March 5, 2014Date of Patent: February 9, 2016Assignee: Vision Global Holdings Ltd.Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Yun Chung Leung
-
Patent number: 9249397Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: GrantFiled: July 27, 2015Date of Patent: February 2, 2016Assignees: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Patent number: 9241907Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.Type: GrantFiled: July 28, 2011Date of Patent: January 26, 2016Assignee: Curemark, LLCInventors: Joan M. Fallon, Matthew Heil
-
Patent number: 9221982Abstract: Mixtures are provided that can include: latex polymer; antifoam; surfactant; plasticizer; ether; fungicide; glycol; and liquid stabilizer. Mixtures comprising: glycol; antioxidant; and defoamer. Compositions are provided that can include: a substrate; and a mixture over the substrate, the mixture comprising one or more of: latex polymer; antifoam; surfactant; plasticizer; ether; fungicide; glycol; liquid stabilizer; and antioxidant. Vehicle tires are provided. Plastic vehicle components are provided. Substrate treatment methods are provided that can include applying compositions to the substrate, the compositions comprising one or more of: latex polymer; antifoam; surfactant; plasticizer; ether; fungicide; glycol; liquid stabilizer; and antioxidant. Vehicle tire treatment methods are provided. Vehicle component treatment methods are provided.Type: GrantFiled: August 18, 2014Date of Patent: December 29, 2015Inventor: Ray Gross
-
Patent number: 9200265Abstract: Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.Type: GrantFiled: November 14, 2012Date of Patent: December 1, 2015Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of Michigan, University of Kentucky Research FoundationInventors: Donald Landry, Chang-Guo Zhan, James H. Woods, Roger Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Victor Yang, Mei-Chuan Holden Ko, Shi-Xian Deng, John J. Tesmer, Tien-Yi Lee, Young Min Kwon, Daquan Gao
-
Patent number: 9133446Abstract: The present invention provides AP that has a high specific activity and preferably has superior reactivity with respect to various luminescent substrates generally used for high-sensitivity immunoassay analysis. Further preferably, the present invention provides AP having a thermal stability higher than that of CIAP. The alkaline phosphatase of the present invention is derived from the genus Shewanella and has the following characteristics: (A) molecular weight: about 104,000; (B) optimum reaction pH: about 9.5; (C) stable pH range: 5.5 to 10.4; (D) thermal stability: 65° C., and (E) specific activity: 5,000 U/mg or more.Type: GrantFiled: August 22, 2013Date of Patent: September 15, 2015Assignee: TOYOBO CO., LTD.Inventors: Hiroshi Aiba, Takahide Kishimoto, Yoshiaki Nishiya
-
Patent number: 9125823Abstract: The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also relates to a slow release system represented by a mixture of a glycogen with a polysaccharide, and its use for the preparation of slow release pharmaceutical or food formulations.Type: GrantFiled: January 8, 2010Date of Patent: September 8, 2015Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Stefano Selva, Leonardo Marchitto, Giovanni Battista Ciottoli, Lorella Ragni, Vincenzo Russo, Elisa Liberati